US pharma firm reaffirms healthcare commitment in China

US pharmaceutical company Eli Lilly and Company has reaffirmed its strong commitment to advancing healthcare in China by participating in the China International Fair for Trade in Services (CIFTIS) for five consecutive years.

Through this platform, the company showcases its cutting-edge products and strengthens clinical research partnerships with local medical institutions. China, as a key strategic market, plays a pivotal role in Lilly's mission to deliver innovative treatments to patients faster, the company said.

"CIFTIS has become a strategic platform for Lilly to expand its presence in China. Over the years, it has evolved from a platform for enhancing brand visibility into a dynamic center for ecosystem development and collaborative innovation," said Huzur Devletsah, Lilly Group vice-president and China general manager.

"Beijing is a strategically important market for us. The city's strong network of top-tier universities, research institutions, and advanced R&D platforms provides solid support for Lilly's innovation incubators. This ecosystem enables Lilly to develop globally competitive medicines," Devletsah said.

She further added that, guided by Lilly's 'In China, for China' philosophy, the company will continue to expand its footprint in the Chinese market with an open and inclusive approach.

By leveraging Beijing's supportive policies and strong scientific research capabilities, Lilly connects critical resources, provides scientific management and professional support to local enterprises, and helps accelerate breakthroughs in next-generation medical innovation.

Meanwhile, Lilly has been strengthening its collaboration with China's healthcare ecosystem partners and regulatory authorities to jointly advance the prevention, diagnosis, and treatment of Alzheimer's disease.

The company is also joining hands with stakeholders across diverse sectors to accelerate progress in obesity care. It continues to ramp up investment in innovative R&D, focusing on delivering breakthrough solutions for individuals living with obesity, overweight, or associated complications.